The present disclosure provides methods of screening and compositions and methods for treating ciliopathy diseases. Methods are provided for screening for molecules to treat ciliopathy disorders by measuring the activity of ubiquitin-proteasome system (UPS)-mediated protein degradation in the presence and the absence of a candidate molecule, wherein an increase of the activity in the presence of the candidate molecule identifies the molecule as a potential therapeutic. The methods provided also include measuring the activity of a ubiquitin peptidase or a Zic family member 1 (ZIC1) gene product, in the presence and absence of a candidate molecule, wherein a decrease in activity in the presence of the molecule identifies it as a potential therapeutic.

The present invention relates to polymer particles and uses thereof. In particular the present invention relates to functionalised polymer particles, processes of production and uses thereof in the diagnosis, treatment or prevention of tuberculosis.

A method for quantitatively assessing muscle contraction of a facial muscle in a person and determining the ability of a treatment material to reduce contraction of the facial muscle is disclosed. The method can include applying an external electrical stimulus to facial skin sufficient to contract a facial muscle, measuring the contractile activity of the contracted facial muscle by measuring the compound motor action potential (CMAP) of the contracted facial muscle to obtain a first average measurement of contractile activity of the contracted facial muscle, administering the treatment material by topically applying the treatment material to the facial skin, and repeating steps (a) and (b) to obtain a second average measurement of contractile activity of the contracted facial muscle.

Glucose-sensing luminescent dyes, polymers, and sensors are provided. Additionally, systems including the sensors and methods of using these sensors and systems are provided.

The present invention provides novel antigens of an allergy to soybean, methods and kits for diagnosing an allergy to soybean, pharmaceutical compositions comprising such an antigen, soybeans or processed products of soybean in which such an antigen is eliminated, and a tester for determining the presence or absence of a soybean antigen in an object of interest. The present invention also relates to polypeptides comprising an epitope of an allergen, kits, compositions and methods for diagnosing an allergy, comprising such a polypeptide, pharmaceutical compositions comprising such a polypeptide, and food raw materials or edible processed products in which an antigen comprising such a polypeptide is eliminated or reduced, or the polypeptide is cleaved or removed. The present invention further relates to a tester for determining the presence or absence of an antigen in an object of interest.

Disclosed is a method for evaluating a cosmetic composition or a component thereof, comprising the steps of: (i) identifying a first individual microbiome network on a skin surface of a person; (ii) treating the skin surface having the identified first individual microbiome network with a cosmetic composition or the component thereof; (iii) identifying a second individual microbiome network on the skin surface that was treated; and (iv) comparing the first and second individual microbiome networks.

Provided herein are devices and methods used to produce tattoo biosensors that are based on spatially controlled intracutaneous gene delivery of optical reporters driven by specific transcription factor pathways for a given cytokine or other analyte. The biosensors can be specific to a given analyte, or more generically represent the convergence of several cytokines into commonly shared intracellular transcription factor pathways. These biosensors can be delivered as an array in order to monitor multiple cytokines. Biosensor redeployment can enable chronic monitoring from months to years. The tattooed biosensor array of the present invention includes endogenous reporter cells, naturally tuned to each patient's own biology and can be used to reliably measure the state of a patient in real-time.

A method for quantitatively assessing muscle contraction of a facial muscle in a person and determining the ability of a treatment material to reduce contraction of the facial muscle is disclosed. The method can include applying an external electrical stimulus to facial skin sufficient to contract a facial muscle, measuring the contractile activity of the contracted facial muscle by measuring the compound motor action potential (CMAP) of the contracted facial muscle to obtain a first average measurement of contractile activity of the contracted facial muscle, administering the treatment material by topically applying the treatment material to the facial skin, and repeating steps (a) and (b) to obtain a second average measurement of contractile activity of the contracted facial muscle.

The present invention provides novel antigens of an allergy to soybean, methods and kits for diagnosing an allergy to soybean, pharmaceutical compositions comprising such an antigen, soybeans or processed products of soybean in which such an antigen is eliminated, and a tester for determining the presence or absence of a soybean antigen in an object of interest.

The present invention related to a matrix, a patch and a method for non-invasive sampling of at least one endogenous substance on a skin surface of an individual, wherein the matrix comprises at least one amphiphile, wherein the amphiphile, alone or in combination with at least one structurally related amphiphile, forms a non-lamellar liquid crystalline phase together with an aqueous polar solvent mixture, said matrix comprising a water activity of at least 0.85 in a temperature range of 20-40 C., wherein the matrix is configured to extract said at least one endogenous substance on the skin surface of the individual.